相似文献
1
Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL): Overview and introduction to the proceedings of the 2016 TACL investigator meeting.
Pediatr Hematol Oncol. 2017 Sep-Oct;34(6-7):349-354. doi: 10.1080/08880018.2017.1377329. Epub 2017 Nov 9.
2
Investigating the biology of relapsed acute leukemia: Proceedings of the Therapeutic Advances for Childhood Leukemia & Lymphoma (TACL) Consortium Biology Working Group.
Pediatr Hematol Oncol. 2017 Sep-Oct;34(6-7):355-364. doi: 10.1080/08880018.2017.1395937. Epub 2017 Nov 30.
3
TACL'ing supportive care needs in pediatric early phase clinical trials for acute leukemia: A report from the therapeutic advances in childhood leukemia & lymphoma (TACL) consortium supportive care committee.
Pediatr Hematol Oncol. 2017 Sep-Oct;34(6-7):409-417. doi: 10.1080/08880018.2017.1395936. Epub 2017 Nov 30.
4
Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium.
J Natl Cancer Inst. 2024 Nov 1;116(11):1721-1729. doi: 10.1093/jnci/djae165.
5
[Monoclonal antibodies for lymphomas and leukemias in 2005].
Bull Cancer. 2006 Jan;93(1):107-18.
6
CE: Hematologic Childhood Cancers: An Evidence-Based Review.
Am J Nurs. 2019 Dec;119(12):34-44. doi: 10.1097/01.NAJ.0000615784.09785.ab.
7
Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study.
Pediatr Blood Cancer. 2010 Sep;55(3):421-9. doi: 10.1002/pbc.22612.
8
Leukemias and lymphomas in children.
Prim Care. 1992 Dec;19(4):853-69.
9
2nd International Congress on Leukemia, Lymphoma and Myeloma.
Expert Rev Hematol. 2009 Oct;2(5):509-12. doi: 10.1586/ehm.09.50.
10
Patients with Down syndrome can be included in early phase clinical trials- a report from the T2016-003 Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) study.
Leukemia. 2023 May;37(5):1138-1140. doi: 10.1038/s41375-023-01856-6. Epub 2023 Feb 22.
引用本文的文献
1
Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium.
J Natl Cancer Inst. 2024 Nov 1;116(11):1721-1729. doi: 10.1093/jnci/djae165.
2
Effect of CB2 Stimulation on Gene Expression in Pediatric B-Acute Lymphoblastic Leukemia: New Possible Targets.
Int J Mol Sci. 2022 Aug 3;23(15):8651. doi: 10.3390/ijms23158651.
3
Immune function in childhood cancer survivors: a Children's Oncology Group review.
Lancet Child Adolesc Health. 2021 Apr;5(4):284-294. doi: 10.1016/S2352-4642(20)30312-6. Epub 2021 Feb 16.
4
Clinical efficacy and safety of 6-thioguanine in the treatment of childhood acute lymphoblastic leukemia: A protocol for systematic review and meta-analysis.
Medicine (Baltimore). 2020 May;99(18):e20082. doi: 10.1097/MD.0000000000020082.
本文引用的文献
1
Phase I Study of Clofarabine and 2-Gy Total Body Irradiation as a Nonmyeloablative Preparative Regimen for Hematopoietic Stem Cell Transplantation in Pediatric Patients with Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia Consortium Study.
Biol Blood Marrow Transplant. 2017 Jul;23(7):1134-1141. doi: 10.1016/j.bbmt.2017.03.037. Epub 2017 Apr 7.
2
A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
Clin Cancer Res. 2016 Aug 15;22(16):4014-22. doi: 10.1158/1078-0432.CCR-15-1998. Epub 2016 Feb 26.
3
A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.
J Pediatr Hematol Oncol. 2014 Aug;36(6):458-63. doi: 10.1097/MPH.0b013e3182a8f58f.
4
Outcome of children and adolescents with a second or third relapse of acute lymphoblastic leukemia (ALL): a population-based analysis of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) study group.
J Pediatr Hematol Oncol. 2013 Jul;35(5):e200-4. doi: 10.1097/MPH.0b013e318290c3d6.
5
Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
Blood. 2012 Jul 12;120(2):285-90. doi: 10.1182/blood-2012-04-418640. Epub 2012 May 31.
6
ABT-751 in relapsed childhood acute lymphoblastic leukemia.
J Pediatr Hematol Oncol. 2012 Oct;34(7):583-4. doi: 10.1097/MPH.0b013e3182532446.
7
Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.
J Clin Oncol. 2012 May 10;30(14):1663-9. doi: 10.1200/JCO.2011.37.8018. Epub 2012 Mar 12.
8
Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study.
Pediatr Blood Cancer. 2010 Sep;55(3):421-9. doi: 10.1002/pbc.22612.
9
Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium.
Pediatr Blood Cancer. 2010 Aug;55(2):254-9. doi: 10.1002/pbc.22456.
10
Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference.
Pediatr Blood Cancer. 2010 Jul 1;54(7):872-8. doi: 10.1002/pbc.22414.
Zotero 插件